Home
    • Plans Blog Contact
    Natera Inc logo

    Natera Inc

    NTRA
    Last price US$261.92
    Market cap US$38.5b
    12M price change 85.54%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    IQVIA Holdings IncIQV Industry peer Agilent Technologies IncA Industry peer Thermo Fisher Scientific IncTMO Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Natera Inc Overview

    Industry: Diagnostics & Research

    Sector: Healthcare

    Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company's products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas. Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Natera Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 07, 2026

    Quarterly result summary

    Revenue was $696.6M (+39% YoY). Net loss was -$85.1M.

    Revenue $696.6M +39% YoY
    Net loss -$85.1M reported

    What changed

    • Revenue +39% YoY to $696.6M.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q May 08, 2026 SEC filing 8-K May 07, 2026 Earnings material Earnings release May 07, 2026 SEC filing 10-K Feb 27, 2026 Earnings release EXHIBIT 99.1 Feb 26, 2026 SEC filing FORM 8-K Feb 26, 2026 Earnings material EXHIBIT 99.2 Feb 26, 2026 Earnings release EXHIBIT 99.1 Jan 12, 2026 SEC filing FORM 8-K Jan 12, 2026 SEC filing 10-Q Nov 07, 2025 SEC filing FORM 8-K Nov 06, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 2.00/5
    Natera Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Diagnostics & Research industry , IQVIA Holdings Inc , Agilent Technologies Inc , Thermo Fisher Scientific Inc are companies with high ratings.

    Return on Equity

    Score 0.85/5
    Natera Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Natera Inc NTRA US$38.5b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 1.82/5
    Natera Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Natera Inc NTRA US$38.5b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Diagnostics & Research industry , IQVIA Holdings Inc , Agilent Technologies Inc , Thermo Fisher Scientific Inc are companies with high ratings.

    Leverage

    Score 2.07/5
    Natera Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Natera Inc NTRA US$38.5b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Natera Inc logo

    Natera Inc

    US$261.92

    US$18.90

    -92.8% vs price

    US$38.5b

    -3.51%

    85.54%